SNDX - Syndax Pharma falls after early data for leukemia therapy
2023-10-02 07:47:20 ET
More on Syndax
- Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results
- Syndax Pharmaceuticals, Inc. (SNDX) Q2 2023 Earnings Call Transcript
- Biggest stock movers today: Syndax Pharmaceuticals, Coinbase Global and more
- Syndax and Incyte gain on mid-stage win for immune disorder therapy
- Seeking Alpha’s Quant Rating on Syndax Pharmaceuticals
For further details see:
Syndax Pharma falls after early data for leukemia therapy